teclistamab,talquetamab,daratumumab
genmab,janssen
['redirectt-1', 'talquetamab', 'mmsm']
congress #eha2023 | mar a-victoria mateos reports on the redirectt-1 study of teclustamab+ talquetamab in patients with rrmm. n=93. orr was 86.6% among all pts &amp; 96.3% at optimal phii dose. for pts with emd= 71.4%. cr= 40% all dose levels. #mmsm #myeloma 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma